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sulfate (100%), Magnesium sulfate (100%) and Ondansetron (70%). In our study total 
cost of drugs (300974.4 rupees), in total cost Ondansetron has 14.7% and least was 
amlodipine of 0.018%. CONCLUSIONS: There are 32 adjunctive drugs used in inpa-
tient oncology department. The drug utilization study we conducted helped to know 
the prescribing and usage pattern of drugs in inpatient radiotherapy department, 
there by the indenting of drugs is very easy without any drug lackage. The cost 
considerations are helped for proper budget preparation.
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OBJECTIVES: Treatment for resected melanoma at high risk for progression has 
generally consisted of adjuvant interferon alfa-2b, the only adjuvant melanoma 
therapy approved in the US. This study sought to describe patterns of systemic adju-
vant therapy, clinical outcomes, and healthcare costs among melanoma patients 
treated in the US community oncology setting. METHODS: This was a retrospective 
observational study of adult patients with Stage I-III melanoma identified between 
1/1/2007 and 4/1/2013 in the Vector Oncology Data Warehouse. Descriptive statistics 
were used to describe patient demographic and clinical characteristics for those 
treated and untreated with systemic adjuvant therapy. Only patients who received 
interferon/peginterferon as their adjuvant systemic therapy were evaluated for 
treatment patterns and clinical outcomes including time to treatment initiation 
and disease-free survival (DFS). Total direct healthcare cost and costs associated 
with systemic therapy were calculated per patient per month (PPPM) based on 
imputation from billing record charges and utilization history. RESULTS: Of the 
636 patients identified, 149 (23.4%) were treated with adjuvant systemic therapy. 
Of these, 137 received interferon/peginterferon therapy. Median time from surgical 
resection to start of interferon/peginterferon was 2.6 months and median duration 
of therapy for patients treated with interferon was 3.5 months. Approximately, 75% 
of patients remained on therapy at one month and by one year, only 25% of the 
patients remained. Median DFS was a little more than three years (38.2 months). 
Median (IQR) total cost associated with first-line systemic therapy was $18,154 
($10,139, $38,477) PPPM; $13,416 ($8,190, $28,725) of that cost was attributable to 
interferon/peginterferon therapy (2014 dollars). CONCLUSIONS: This study suggests 
that in this community oncology setting, adjuvant melanoma treatment comprised 
mostly interferon/peginterferon therapy. Only 25% of patients received the full rec-
ommended 1-year course of interferon therapy. These results highlight the need for 
better and more tolerable treatments in the adjuvant setting.
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OBJECTIVES: Across geographies, governments and institutions are implementing 
additional administrative burdens on clinicians while prescribing high cost oncology 
products. In an effort to reduce prescriptions and control healthcare expenditure, 
these restrictions have been put in place as a means of prescription justification and 
to ensure careful thought has been invested into each patient. This research sought 
to investigate the prevalence, impact and outcomes of such schemes. METHODS: 
The research was conducted through in-depth interviews with payers and clinicians 
across 10 EMEA markets. RESULTS: In many markets studied, there are systems 
currently in place to ensure appropriate prescription of high cost products. These 
additional requirements may be manifested in supplemental forms that must be 
filled out by the prescribing clinician (e.g. Norway), online patient registrations 
and database entry (e.g. Italy), additional pharmacist justification (Saudi Arabia) 
or additional physician justification (e.g. Slovakia). CONCLUSIONS: Payers viewed 
some protocols as being more effective than others to combat adverse prescrip-
tion, while clinicians viewed them as being time consuming and often annoying. 
Interestingly, physicians found loop-holes as a way to avoid the additional burden 
and time required to prescribe high cost oncology products. Physicians were not 
concerned with these systems permanently restricting access of high cost products 
to their patients. However, their main concern was that these additional procedures 
are causing delays in the initiation of treatment and require additional effort.
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OBJECTIVES: The Cancer Care Quality Program (CCQP), a novel program by Anthem 
Inc. health plans designed to align reimbursement with evidence-based, cost-effec-
tive oncology treatment, collects clinical data that can be integrated with the admin-
istrative claims data in the HealthCore Integrated Research Database (HIRD). This 
study evaluated baseline characteristics of patients within oncology practices par-
ticipating in the CCQP. METHODS: Breast, colon, and lung cancer patients from prac-
tice sites participating in the CCQP were identified between 6/23/2014 and 12/3/2014 
(Intake Period). Patients were characterized based on the earliest request to utilize 
chemotherapy and/or supportive care medications (Index Date) during the Intake 
Period; analyses included patients with ≥ 6 months of continuous pre-index eligibil-
ity. CCQP clinical data was integrated with HIRD administrative claims data. Baseline 
characteristics were stratified by cancer type/stage and included: pathology, bio-
markers, ECOG performance status, and Deyo-Charlson Index (DCI). RESULTS: A 
total of 1,230 breast, 329 colon, and 554 lung cancer patients were identified with 
mean(SD) ages and DCI’s of 55(11), 58(10), and 62(9) and 5.7(3.2), 7.6(2.6), and 7.7(2.8), 
at a provincial level may be required to offset the inherent uncertainty in the 
resulting ICER estimation.
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OBJECTIVES: The Appalachia region experiences excess cancer mortality and a lack 
of access to cancer care resources. There is limited research examining adjuvant 
treatment use disparities in this region. This study aims to explore adjuvant endo-
crine therapy (AET) utilization in Appalachia, and delineate the effects of access 
to cancer on AET use. METHODS: We linked female breast cancer patients identi-
fied in cancer registries from the Appalachian counties in four states (KY, NC, OH, 
PA) to 2006-2008 Medicare claims data. We included patients with invasive, non-
metastatic, hormone-receptor-positive breast cancer and assessed the prevalence 
of receiving guideline-recommended AET. We then assessed AET adherence among 
those who received guideline-recommended AET using the Medication Possession 
Ratio (MPR), and determined non-persistence, defined as exceeding a 60-day medi-
cation gap. We also used survival analyses to examine the influences of adherence 
and persistence on overall survival. RESULTS: Only 450 of the 946 eligible patients 
(47.6%) received guideline-recommended AET, which was significantly associated 
with shorter travel time to receive care, dual Medicare and Medicaid eligibility, being 
unmarried (vs. married), and living in Pennsylvania (vs. Ohio). The non-adherence 
rate was about 31% and non-persistence rate was 30% over an average follow-up 
period of 421 days. Tamoxifen, relative to aromatases, was associated with higher 
odds of adherence (OR = 2.82, p < 0.001) and a lower risk of non-persistence (HR = 
0.40, p < 0.001). Side effects like pain may be an important factor leading to non-
adherence and early discontinuation. Non-adherence to and non-persistence with 
AET were associated with higher risks of all-cause mortality. CONCLUSIONS: In 
Appalachia, geographic and socioeconomic factors such as travel time to receive 
care and healthcare plan type are important elements that could contribute to 
disparities in access to adjuvant treatment, while treatment choice and medication-
related factors may exert strong influences on AET use behaviors.
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OBJECTIVES: Cancer survivors have been reported delaying or avoiding care due 
to costs. Cost-related medication nonadherence (CRN) is associated with worse 
health outcomes, including stroke, heart disease, and hospitalizations. This study 
was conducted to estimate the prevalence and factors of CRN among cancer sur-
vivors. METHODS: Using the 2013 Behavioral Risk Factor Surveillance System 
(BRFSS), we will examine self-reported CRN among cancer survivors. In total, 
491,773 subjects, including 44,968 (0.09%) cancer survivors, who reported CRN 
in the past 12 months were identified. Descriptive statistics and multiple logis-
tic regression models were used to characterize and to identify factors affecting 
CRN among cancer survivors. RESULTS: In a nationally representative sample 
of 44,968 cancer survivors, 3,328 (7.4%) were CRN-reported (851 men and 2,477 
women). Cancer survivors who reported CRN (n= 3,328) were younger, live in the 
South, more likely to be less educated, more likely to be female and Hispanic, 
and more likely to have health care coverage, lower household income, multiple 
comorbidities, poorer self-rated health status, and activity limitation. In adjusted 
analyses, men with younger age, black or Hispanic race, lower household income, 
no health care coverage, health care coverage, multiple comorbidities, poorer self-
rated health, and activity limitation were significantly more likely to report CRN. 
Women with younger age, Hispanic or other race, South living, lower household 
income, higher education, no health care coverage, health care coverage, multiple 
comorbidities, poorer self-rated health, and activity limitation were significantly 
more likely to report CRN. CONCLUSIONS: Significant gender-specific differences 
were found among factors related to CRN among cancer survivors. Given the high 
cost sharing under drug coverage, it is important to closely monitor CRN in high-
risk subgroups. Further studies are warranted to establish effective interventions 
in this vulnerable population.
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OBJECTIVES: The objective of adjunctive drug utilization pattern is to know the 
proportion of adjunctive drugs used in cancer inpatient’s , to improve the quality of 
health care, for proper planning of indenting and budgeting of adjunctive drugs in 
Oncology (Radiotherapy) Department. METHODS: The study was conducted in the 
Oncology (Radiotherapy) Department of Guntur Medical College and Government 
General Hospital, Guntur. The study method includes prioritizing the patients based 
on inclusion and exclusion criteria. Information regarding drug utilization is col-
lected with the aid of a data collection form from the inpatient’s case sheets. The col-
lected data will be tabulated and analyzed using suitable statistical tools. RESULTS: 
The most commonly observed cancer type was cervix ( 26.54%) followed by Head 
and Neck ( 23.9%). In our study, we observed that there is more prevlence(80%) of 
gynaecological cancers in women. There was female predominance (67%) in cancer 
prevalence. The present study shows maximum number of patients are between 
the age group of 40- 60 years (33.6%). The total drugs used in inpatient oncology 
department are 70450, among all the drugs 16015 are parenteral formulations, 
whereas 54435 are oral formulations. Ondansetron is the mostly used drug (17.5%) 
followed by diclofenac (12.7%) and ranitidine (12.5%). The drugs use for prevention 
of chemotherapy induced adverse drug reactions include mesna (100%), Potassium 
